Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant

ConclusionsRimegepant 75  mg, which has been shown to be associated with reduced MMD, is associated with improvement in MSQv2 domains over time, leading to estimated improvement in EQ-5D-3L utilities. While this improvement was observed in all patient-groups, it was most pronounced in those with higher MMD and those taking rimegepant QOD + PRN.Trial registrationClinical Trials NCT03266588.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research